Abstract
Maintenance treatment with durvalumab after completion of chemoradiotherapy (CRT) in PD-L1-positive patients with inoperable stage III NSCLC is the international standard therapy. Treatment intensification with concurrent immunotherapy is controversial discussed. In this prospective study, we evaluated the role of concurrent versus sequential immunotherapy in patients receiving platinum-based CRT for stage III NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
